alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     This schedule  contains summary  financial  information  extracted from the
Balance  Sheet and  Statement  of  Operations  as of and for the 39 weeks  ended
October 30, 1999 and is qualified in its entirety by reference to such financial
statements as included in the Company's Quarterly Report on Form 10-Q.
</LEGEND>
<CIK>                                             0000813775
<NAME>                                            Factory 2-U Stores, Inc.
<MULTIPLIER>                                      1,000


<S>                                               <C>
<PERIOD-TYPE>                                     9-MOS
<FISCAL-YEAR-END>                                 JAN-29-2000
<PERIOD-START>                                    AUG-1-1999
<PERIOD-END>                                      OCT-30-1999
<CASH>                                            4,341
<SECURITIES>                                      0
<RECEIVABLES>                                     1,371
<ALLOWANCES>                                      28
<INVENTORY>                                       54,233
<CURRENT-ASSETS>                                  63,019
<PP&E>                                            41,792
<DEPRECIATION>                                    16,478
<TOTAL-ASSETS>                                    120,948
<CURRENT-LIABILITIES>                             69,805
<BONDS>                                           0
<PREFERRED-MANDATORY>                             0
<PREFERRED>                                       0
<COMMON>                                          124
<OTHER-SE>                                        34,853
<TOTAL-LIABILITY-AND-EQUITY>                      120,948
<SALES>                                           281,581
<TOTAL-REVENUES>                                  281,581
<CGS>                                             181,571
<TOTAL-COSTS>                                     181,571
<OTHER-EXPENSES>                                  92,675
<LOSS-PROVISION>                                  0
<INTEREST-EXPENSE>                                1,824
<INCOME-PRETAX>                                   5,511
<INCOME-TAX>                                      2,259
<INCOME-CONTINUING>                               3,252
<DISCONTINUED>                                    0
<EXTRAORDINARY>                                   0
<CHANGES>                                         0
<NET-INCOME>                                      3,252
<EPS-BASIC>                                     0.27
<EPS-DILUTED>                                     0.25





</TABLE>
<PAGE>   1
                                                               Exhibit 5



August 21, 1997


                                                               (206) 389 1604

                                                               INTERNET
                                                               bstephens@gj.com



Innova Corporation
Gateway North, Building 2
3325 South 116th Street
Seattle, Washington 98168-1974

RE:         FORM S-8 REGISTRATION STATEMENT

Ladies and Gentlemen:

We have acted as counsel to Innova Corporation (the "Company") in connection
with the preparation of its Registration Statement on Form S-8 (the
"Registration Statement") under the Securities Act of 1933, as amended (the
"Act"), which the Company will file with the Securities and Exchange Commission,
with respect to an aggregate of 2,043,005 shares of Common Stock of the Company
(the "Shares") issuable upon exercise of options granted or to be granted under
the Company's 1990 Stock Option Plan (Amended and Restated July 31, 1992) (the
"Plan").

We have examined the Registration Statement and such other documents and records
as we have deemed relevant and necessary for the purpose of this opinion.

Based upon and subject to the foregoing, we are of the opinion that the Shares
issuable under the Plan will, upon due execution by the Company and the
registration by its registrar of the certificates for the Shares and issuance
thereof by the Company and receipt by the Company of the consideration therefor
in accordance with the terms of the Plan, be validly issued, fully paid and
nonassessable.

We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement. In giving such consent, we do not admit that we are in
the category of persons whose consent is required under Section 7 of the Act.






<PAGE>   2


Innova Corporation
August 21, 1997
Page 2
--------------------------------------------------------------------------------


Very truly yours,

/s/ BENJAMIN F. STEPHENS


Benjamin F. Stephens
            of
GRAHAM & JAMES LLP/RIDDELL WILLIAMS P.S.
1

Motion Denied and Order filed December 31, 2020 

In The

Fourteenth Court of Appeals

____________

NO. 14-19-00905-CV

____________

DIAMOND OFFSHORE DRILLING, INC. AND DIAMOND RIG 

INVESTMENTS LTD, Appellants

V.

WILLIAM BLACK, Appellee

On Appeal from the 281st District Court

Harris County, Texas

Trial Court Cause No. 2015-74728

ORDER

We abated this appeal because appellants filed a petition for bankruptcy. The 

parties have now filed a joint motion to reinstate the appeal and set a briefing 

schedule. Attached to the motion is an order (“the Order”) from the bankruptcy court 

that is represented as an order allowing this appeal to proceed.

Interpreting the scope and effect of a bankruptcy court’s order modifying the 

automatic stay in a pending bankruptcy case raises primarily issues of federal law, 
2

not state law. Davis v. Baker, 29 S.W.3d 921, 924 (Tex. App.—Austin 2000, order), 

disp. on merits, No. 03-99-00849-CV, 2001 WL 1379872 (Tex. App.—Austin Nov. 

8, 2001, no pet.) (not designated for publication). An order lifting the automatic stay 

must be construed strictly. Casperone v. Landmark Oil & Gas Corp., 819 F.2d 112, 

114 (5th Cir. 1987) (“Because a section 362 stay freezes in place all proceedings 

against the debtor, and because only an order of the bankruptcy court can authorize 

any further progress in the stayed proceedings, it follows that the continuation of any 

proceeding can derive legitimacy only from the bankruptcy court order. The terms 

of an order modifying the automatic stay must therefore be strictly construed.”).

The Order concerns multiple lawsuits, not just the one underlying this appeal. 

The lawsuit underlying this appeal is referred to in the Order as the “Black State 

Court Litigation” and is defined as the claims pending in “the 281st Judicial District 

Court of Harris County, Texas, captioned William Black v. Diamond Offshore 

Drilling, Inc., et al., Case No. 2015-74728.” The Order states in relevant part:

The Automatic Stay shall be lifted with respect to the Black State Court 

Litigation.

. . . 

Except as expressly modified herein, the Automatic Stay shall remain 

in place for all other purposes.

Nowhere does the Order mention this appeal by name or case number, nor does the 

order suggest that the Black State Court Litigation should be construed to include 

any appeals that arise from that litigation. It is not reasonable to construe the Order 

as lifting the automatic stay with respect to this appeal.

Therefore, the motion is denied without prejudice to refiling. 

PER CURIAM

Panel consists of Justices Zimmerer, Spain, and Poissant.
1 Brunner, Christine

From: Sargeant, Kathryn Sent: Thursday, February 06, 2014 12:57 PM To: Higgins, Cortney Subject: Follow-up from 2/5 Tier 3 briefing Attachments: benefits slide for margo schwab.pptx; Summary of Pe er Review Comments rev1A.docx; CL_Summary_12Jan2012.docx; EnSys Peer Review - Fina l Report Delivered 121911a.docx

Cortney, at yesterday’s briefing we committed to a couple of follow-up items.

First, Margo Schwab requested a slide similar to sl ide 17 of yesterday’s briefing, but which includes the figures from the proposal. I am attaching that here.

Second, Amanda Thomas was interested in the refiner y model peer review. We have not completed our documentation of the peer review we conducted for this final rule (it is actively underway), but I am attaching thos e documents associated with the first peer review (for the prop osal). This will give you a feeling for the types of documentation we develop.

Will you please share this material with Margo and Amanda? Feel free to let me know if you have any other ques tions (734-214-4441).
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7364 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7364

 To prohibit a person from advertising for sale a product produced or 
  manufactured using the forced labor of individuals in the People's 
               Republic of China, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 15, 2024

  Mr. Curtis introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
 To prohibit a person from advertising for sale a product produced or 
  manufactured using the forced labor of individuals in the People's 
               Republic of China, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``No Forced Labor on TV Act''.

SEC. 2. PROHIBITION REGARDING PRODUCTS PRODUCED USING FORCED LABOR.

    (a) Prohibition.--A person may not advertise for sale a covered 
product.
    (b) Enforcement by Commission.--
            (1) Unfair or deceptive acts or practices.--A violation of 
        this section shall be treated as a violation of a regulation 
        under section 18(a)(1)(B) of the Federal Trade Commission Act 
        (15 U.S.C. 57a(a)(1)(B)) regarding unfair or deceptive acts or 
        practices.
            (2) Powers of commission.--The Commission shall enforce 
        this section in the same manner, by the same means, and with 
        the same jurisdiction, powers, and duties as though all 
        applicable terms and provisions of the Federal Trade Commission 
        Act (15 U.S.C. 41 et seq.) were incorporated into and made a 
        part of this section. Any person who violates this section 
        shall be subject to the penalties and entitled to the 
        privileges and immunities provided in the Federal Trade 
        Commission Act.
    (c) Definitions.--In this section:
            (1) Commission.--The term ``Commission'' means the Federal 
        Trade Commission.
            (2) Covered product.--The term ``covered product'' means a 
        product produced or manufactured, in whole or in part, using 
        the forced labor of individuals in the People's Republic of 
        China.
            (3) Forced labor.--The term ``forced labor''--
                    (A) has the meaning given that term in section 307 
                of the Tariff Act of 1930 (19 U.S.C. 1307); and
                    (B) includes convict labor and indentured labor 
                under penal sanctions.
    (d) Effective Date.--This section shall take effect on the date 
that is 180 days after the date of the enactment of this Act.
                                 <all>
```
Exhibit 32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 10-K of Capitala Finance Corp. (the Company) for the annual period ended December 31, 2014, as filed with the Securities Exchange Commission on the date hereof (the Report), I, Joseph B. Alala III, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 1.

          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2.

          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: March 4, 2015 /s/ Joseph B. Alala IIIJoseph B. Alala III Chief Executive Officer(Principal Executive Officer) Capitala Finance Corp.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JAN-31-1999
<PERIOD-START>                             MAY-01-1998
<PERIOD-END>                               JUL-31-1998
<CASH>                                          52,589
<SECURITIES>                                         0
<RECEIVABLES>                                   90,737
<ALLOWANCES>                                   (3,757)
<INVENTORY>                                     53,821
<CURRENT-ASSETS>                               211,548
<PP&E>                                          70,567
<DEPRECIATION>                                  30,384
<TOTAL-ASSETS>                                 277,342
<CURRENT-LIABILITIES>                          136,975
<BONDS>                                        159,892
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           182
<OTHER-SE>                                    (21,444)
<TOTAL-LIABILITY-AND-EQUITY>                   277,342
<SALES>                                        140,146
<TOTAL-REVENUES>                               140,146
<CGS>                                           95,011
<TOTAL-COSTS>                                   95,011
<OTHER-EXPENSES>                                22,777
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               4,035
<INCOME-PRETAX>                                 18,323
<INCOME-TAX>                                     6,588
<INCOME-CONTINUING>                             11,702
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,702
<EPS-PRIMARY>                                     0.58
<EPS-DILUTED>                                        0
        

</TABLE>
§ 1114.9 Amendments. ( a ) *General.* FDA may request, or an applicant may submit on its own initiative, an amendment to a PMTA containing information that is necessary for FDA complete the review of a pending PMTA. An amendment must include the appropriate form and specify the STN assigned to the original submission and, if submitted other than at FDA's request, the reason for submitting the amendment. An amendment must also include the certification statement set forth in § 1114.7(m), with the appropriate information inserted, and signed by an authorized representative of the applicant.
( b ) *Review of an amendment.* Submission of an amendment may affect the timing of review of an amended submission as follows: ( 1 ) If the amendment is a major amendment (*e.g.,* an amendment that contains significant new data from a previously unreported study, detailed new analyses of previously submitted data, or substantial new manufacturing information), FDA will restart the 180-day review period after receipt of the amendment.
( 2 ) If FDA requests a minor amendment (*i.e.,* an amendment that is not a major amendment) and receives a written response submitting the requested amendment, FDA may pause the review period for the number of days elapsed between the date of the request and the date that FDA receives the written response.
( c ) *Failure to respond to amendment request.* If FDA requests an amendment and the applicant does not respond within the time period specified in FDA's request, FDA may consider the applicant to have submitted a request to voluntarily withdraw the pending PMTA under § 1114.11 and issue an acknowledgment letter notifying the applicant of the withdrawal.
( d ) *No amendment to closed or withdrawn application.* An applicant may not amend an application after FDA has closed the application through an action under § 1114.29 or it has been withdrawn under § 1114.11.
<PAGE>

                                                                   Exhibit 10.34

                   [LETTERHEAD OF ASTEA INTERNATIONAL INC.]


                               February 17, 1998

PERSONAL AND CONFIDENTIAL

Robert G. Schwartz, Jr.
[ADDRESS REDACTED]

Dear Bob:

     As you and I have discussed, in consideration for your agreement to
continue your employment with Astea International Inc. (the "Company"), the
Company agrees that if at any time the Company terminates your employment for
any reason other for "cause" (defined below), the Company shall pay you the
equivalent of three (3) months of your salary and benefits, to be payable as if
you were continuing as an employee.

     "Cause" is defined as conduct, as determined by the Board of Directors,
involving one or more of the following: (i) gross misconduct that is materially
injurious to the Company; or (ii) the commission of an act of embezzlement,
fraud or deliberate disregard of the rules or policies of the Company which
results in material economic loss, damage or injury to the Company; or (iii) the
unauthorized disclosure of any trade secret or confidential information of the
Company; or (iv) the commission of an act that induces any customer or
prospective customer of the Company to break a contract with the Company or to
decline to do business with the Company; or (v) your conviction of a felony
involving any financial impropriety or which would materially interfere with the
your ability to perform your services or would otherwise be injurious to the
Company; or (vi) your failure to perform in a material respect your employment
obligations without good reason.  In making such determination, the Board of
Directors shall act fairly and in utmost good faith.  If your employment is
terminated for cause, you will be notified of this at the time of termination.

     If this is consistent with your understanding of our agreement, please
indicate this by signing below.

                                 Very truly yours,

                                 /s/  Zack B. Bergreen

                                 Zack B. Bergreen
                                 Chief Executive Officer

AGREED TO:


/s/ Robert G. Schwartz, Jr.
-----------------------------------
Robert G. Schwartz, Jr.


                                      50
[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Page 9398]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4028]


=======================================================================
-----------------------------------------------------------------------

CONSUMER PRODUCT SAFETY COMMISSION


Sunshine Act Meetings

TIME AND DATE: Wednesday, March 3, 2010; 2 p.m.

Place: Hearing Room 420, Bethesda Towers, 4330 East-West Highway, 
Bethesda, Maryland.

Status: Closed to the Public.

MATTERS TO BE CONSIDERED: 

Compliance Status Report

    The Commission staff will brief the Commission on the status of 
compliance matters.
    For a recorded message containing the latest agenda information, 
call (301) 504-7948.

CONTACT PERSON FOR MORE INFORMATION: Todd A. Stevenson, Office of the 
Secretary, U.S. Consumer Product Safety Commission, 4330 East-West 
Highway, Bethesda, MD 20814, (301) 504-7923.

    Dated: February 22, 2010.
Todd A. Stevenson,
Secretary.
[FR Doc. 2010-4028 Filed 3-1-10; 8:45 am]
BILLING CODE 6355-01-M
#### § 211.192 Production record review.

All drug product production and control records, including those for packaging and labeling, shall be reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed. Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records) or the failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated, whether or not the batch has already been distributed. The investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy. A written record of the investigation shall be made and shall include the conclusions and followup.
### Devany, Dennis 

## (OSU From: Wom14@aol.com 

### Sent: Saturday, February 13. 2010 9:54 AM**i'o-t~'** ! "Devany, Dennis (OST) 

### Subject: (no subject) 

### Attachments:
_ legislature e-mail.dog_**-~ ~::.**  "':**':~f -"':~:~_~'j**  , Further to the attached, I urge you to support Colgan's EAS bid
... it just makes sense. William Morgan Morrisonville, NY

1
Exhibit 21.1

                          SUBSIDIARIES OF VIATEL, INC.


                                             JURISDICTION OF INCORPORATION
NAME OF SUBSIDIARY:                                 OR ORGANIZATION:
------------------                           -------------------------------

Viatel U.K. Limited                                   United Kingdom
Viaphone S.R.L.                                       Italy
Viatel S.R.L.                                         Italy
Viatel Operations, S.A.                               France
Viatel S.A.                                           France
Viafon Dat Iberica, S.A.                              Spain
Viatel Global Communications Espana S.A.              Spain
Viatel Belgium SA/NV                                  Belgium
Viaphone SA/NV                                        Belgium
Viatel Gmbh                                           Germany
Viaphone Gmbh                                         Germany
Viatel AG                                             Switzerland
Viaphone AG                                           Switzerland
Viatel Global Communications BV                       Netherlands
Viafoperations BV                                     Netherlands
Viacol Ltda.                                          Colombia
Viatel Colombia Management, Inc.                      Delaware
Viatel Colombia Holdings, Inc.                        Delaware
Viatel Sales U.S.A., Inc.                             Delaware
YYC Communications, Inc.                              Delaware
Viatel Nebraska, Inc.                                 Delaware
Viatel Sweden, Inc.                                   Delaware
Viatel Finland, Inc.                                  Delaware
Viatel Argentina Holdings, Inc.                       Delaware
Viatel Argentina Management, Inc.                     Delaware
Viatel Brazil Management, Inc.                        Delaware
Viatel Brazil Holdings, Inc.                          Delaware